Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

3.90GBp
9 Dec 2016
Change (% chg)

0.21p (+5.54%)
Prev Close
3.79p
Open
4.01p
Day's High
4.01p
Day's Low
4.00p
Volume
2,455,086
Avg. Vol
4,364,736
52-wk High
8.45p
52-wk Low
2.98p

Summary

Name Age Since Current Position

Lorenzo Tallarigo

64 2016 Non-Executive Chairman of the Board

John Dawson

56 2008 Chief Executive Officer, Executive Director

Andrew Heath

66 2011 Non-Executive Deputy Chairman of the Board, Senior Independent Director

Tim Watts

57 2012 Chief Financial Officer, Company Secretary, Executive Director

Peter Nolan

62 2014 Executive Director, Chief Business Officer

Martin Diggle

52 2012 Non-Executive Director

Stuart Henderson

2016 Non-Executive Director

Biographies

Name Description

Lorenzo Tallarigo

Dr. Lorenzo Tallarigo, M.D. has been appointed as Non-Executive Chairman of the Board of the Company, effective 1 February 2016. From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver diseases. Intercept's NASDAQ IPO in 2012 was one of the most successful ever and today the company is valued at $3.7 billion. From 2009 to 2014, Dr. Tallarigo also held the position of Chief Executive Officer at Genextra, a holding company focused on identifying innovative research and projects in life sciences to develop novel treatments and tools by creating successful business ventures, including a 30 per cent. shareholding in Intercept Pharmaceuticals. Under his leadership at Genextra, where he continues as a current Board member, Dr. Tallarigo raised finance to support the activities of several healthcare companies acting in a variety of therapeutic areas. From 1985 to 2008, Dr. Tallarigo worked at Eli Lilly, where he held various positions in areas of clinical research, pharmaceutical product management and marketing and general management, and latterly as its President of international operations. During his latter role at Eli Lilly, Dr. Tallarigo was responsible for $8 billion of revenues and $4 billion in profits, covering 140 countries and managing 12,000 employees. Dr. Tallarigo was formerly a member of the board of trustees for the University of Indianapolis and a member of the international committee of the Indiana University Foundation. He has a Doctor of Medicine degree from the University of Pisa (Italy) and a PMD from Harvard Business School in Boston.

John Dawson

Mr. John Dawson serves as Chief Executive Officer, Executive Director of Oxford BioMedica Plc. From 1996 to 2007, Mr Dawson held senior management positions in the European operations of Cephalon Inc. including, from 2005, a management board position as Chief Financial Officer and Head of Business Development, Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to revenue of several hundred million US dollars. In 2005, Mr Dawson led the US$360 million acquisition of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited. Mr Dawson is a non-Executive director of Paion AG.

Andrew Heath

Dr. Andrew J. Heath, M.D., Ph.D., serves as Non-Executive Deputy Chairman of the Board, Senior Independent Director of Oxford BioMedica PLC. Dr Heath is a biopharmaceutical executive with in-depth knowledge of US and UK capital markets and international experience in marketing and sales, R & D and business development. He was Chief Executive Officer of Protherics plc from 1997 to 2008, taking the Company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, Dr Heath held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director.

Tim Watts

Mr. Tim Watts serves as Chief Financial Officer, Company Secretary, Executive Director of Oxford BioMedica PLC. Mr Watts has 25 years experience in the Pharmaceutical and Biotech sectors. From 1 January 2014 he has been a Director of the UK BioIndustry Association. In 1985 he joined ICI, initially in the corporate headquarters and from 1990 in the pharmaceuticals division, eventually becoming Finance Director of the Zeneca Pharmaceuticals business. Following the merger of Astra and Zeneca, Mr Watts became Group Financial Controller of AstraZeneca PLC in 2001. In 2007 he left AstraZeneca to become Chief Financial Officer at Archimedes Pharma. Mr Watts is a member of the Institute of Chartered Accountants in England and Wales.

Peter Nolan

Mr. Peter Nolan serves as Chief Business Officer, Executive Director of Oxford Biomedica Plc. Peter Nolan was appointed to the Board in May 2002 having been a senior member of the Group since its foundation and has been the architect of the Group’s IP strategy. His current additional operational responsibilities include Business Development, Contracts/Legal Issues, Quality, Health & Safety and Facilities. Until the end of 2013 he was a Director of the UK BioIndustry Association and he is a past founding Chairman of the Oxfordshire Bioscience Network. Prior to joining Oxford BioMedica, Mr Nolan served as Head of the Biotechnology Unit at the UK Department of Trade and Industry for eight years. In that role he was responsible for establishing and managing complex collaborative research programmes involving industry, research councils and other government departments. Previously he held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory in London where he was a senior forensic scientist.

Martin Diggle

Mr. Martin Diggle serves as Non-Executive Director of Oxford BioMedica PLC. Mr Diggle is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund which is the Group’s second largest shareholder. An investment professional with 30 years experience in investment banking and fund management, Mr Diggle has extensive, first-hand knowledge of the global financial markets and is an expert in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003. He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade. Mr Diggle holds a master’s degree in Philosophy, Politics and Economics from University of Oxford, and he is a non-Executive Director of Proteome Sciences plc and Chronos Therapeutics.

Stuart Henderson

Mr. Stuart Henderson has been appointed as Non-Executive Director of the Company, effective 1 June 2016. He joins Oxford BioMedica from Deloitte, where he was Head of European Healthcare and Life Sciences and also served on the Global Industry Team for seven years between 2004 and 2011. Prior to this he was Partner at Arthur Andersen from 1982 to 2002, where he sat on the Andersen Global Life Sciences Team as Head of Emerging Biotechnology. Mr. Henderson has extensive experience in audit and transaction support practice and has worked with life science businesses from start up to multinational as well as acting as reporting accountant on numerous IPO and Class 1 transactions. He has reported as Audit Partner to the audit committees of publicly quoted companies for over 20 years. Mr Henderson is a former director of the Babraham Institute and currently sits as an observer on the board of OneNucleus, the Life Sciences trade body for Cambridge and London.

Basic Compensation

Name Fiscal Year Total

Lorenzo Tallarigo

--

John Dawson

680,000

Andrew Heath

46,000

Tim Watts

425,000

Peter Nolan

377,000

Martin Diggle

--

Stuart Henderson

--
As Of  30 Dec 2014

Options Compensation